New Delhi, April 27, 2016:World Health Organization has made conditional recommendation for use of Bedaquiline for treatment of Multi drug resistant TB in adult patients. An Expert Committee on Regulation of Newer anti-TB drugs in India examined the matter and approved the drug for conditional use in Revised National TB Control Programme (RNTCP).
The drug has been approved by the Drug Controller General of India under Conditional Access Programme for its use only through Revised National TB Control Programme.
The said drug has been tested in human beings by the producer, i.e. Janssen in phase II, stage 1 and stage 2 clinical trials which were conducted in different settings. A total of 515 patients were given the new drug for 24 weeks in the above mentioned trials.
Hubli, May 20, 2024: In a significant move to support child nutrition through effective logistical contributions,…
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…